Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,776.00
(
-1.48%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.30
(
6.60%
)
Bitcoin
71,306.40
(
-3.56%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 74831

Sunday, 03/22/2009 12:47:19 AM

Sunday, March 22, 2009 12:47:19 AM

Post# of 257257
In the "12+12" arm of PROVE-3, the % with undetectable virus at 12 weeks (end of Telaprevir portion of treatment) was 75% (86/115), and the % with undetectable virus at 24 weeks (end of all treatment) was 70% (80/115 or 81/115). (These numbers were reported in June 2008: #msg-29896176). Thus, 5 or 6 of the 86 patients in question had a viral breakthrough while on the SoC portion of the regimen.

Corresponding data for the "24+24" arm have not been disclosed.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now